📊 CUE Key Takeaways
Is Cue Biopharma, Inc. (CUE) a Good Investment?
Cue Biopharma exhibits severe financial distress with massive operating losses (-96.7% margin) despite 7,793% revenue growth, indicating unsustainable burn rate and pre-commercial stage losses. The company is burning cash at an alarming rate (-$21.7M operating cash flow on $27.5M revenue) and will exhaust its $27.1M cash reserve within 14 months at current burn, leaving minimal runway for clinical development.
Cue Biopharma shows a sharp revenue increase, but profitability quality remains weak because operating and net margins are still deeply negative and free cash flow remains materially negative. The balance sheet is relatively clean with no long-term debt and solid near-term liquidity, but continued cash burn and negative returns on assets and equity suggest the business model is not yet financially self-sustaining.
Why Buy Cue Biopharma, Inc. Stock? CUE Key Strengths
- Strong liquidity position with $27.1M cash and 2.74x current ratio providing near-term operational flexibility
- Dramatic 7,793% revenue growth suggests early commercialization or partnerships beginning to generate income
- Zero long-term debt reduces financial leverage risk and future solvency concerns
- Strong liquidity with $27.14M in cash and a 2.74x current ratio
- No long-term debt, which reduces balance-sheet risk
- Revenue growth was exceptionally strong year over year, indicating potential partnership or milestone-driven inflows
CUE Stock Risks: Cue Biopharma, Inc. Investment Risks
- Severe cash burn of -$21.9M free cash flow with only 14 months of runway at current burn rate before insolvency
- Operating margin of -96.7% and net margin of -96.9% indicate fundamental unprofitability and no path to profitability visible
- Negative ROE (-100.6%) and ROA (-63.0%) demonstrate value destruction and inefficient capital deployment
- Operating cash outflows of -$21.7M on $27.5M revenue indicates business model not yet sustainable
- Operating and net margins remain near -97%, showing severe unprofitability
- Free cash flow of -$21.86M indicates continued heavy cash burn
- Revenue growth quality may be weak or non-recurring if driven by milestone or collaboration payments rather than durable commercialization
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Path to operating profitability and timeline to breakeven
- Revenue growth sustainability and gross margin realization
- Quarterly operating cash burn relative to cash balance
- Sustainability and composition of revenue growth versus recurring operating losses
Cue Biopharma, Inc. (CUE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.74x current ratio provides a solid financial cushion.
CUE Profit Margin, ROE & Profitability Analysis
CUE vs Healthcare Sector: How Cue Biopharma, Inc. Compares
How Cue Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cue Biopharma, Inc. Stock Overvalued? CUE Valuation Analysis 2026
Based on fundamental analysis, Cue Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cue Biopharma, Inc. Balance Sheet: CUE Debt, Cash & Liquidity
CUE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cue Biopharma, Inc.'s revenue has grown significantly by 84% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.72 indicates the company is currently unprofitable.
CUE Revenue Growth, EPS Growth & YoY Performance
CUE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.1M | -$7.4M | $-0.07 |
| Q2 2025 | $2.7M | -$8.5M | $-0.09 |
| Q1 2025 | $421.0K | -$12.3M | $-0.17 |
| Q3 2024 | $2.1M | -$8.7M | $-0.17 |
| Q2 2024 | $1.4M | -$10.2M | $-0.20 |
| Q1 2024 | $187.0K | -$12.3M | $-0.25 |
| Q3 2023 | $68.0K | -$11.0M | $-0.24 |
| Q2 2023 | $26.0K | -$13.2M | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cue Biopharma, Inc. Dividends, Buybacks & Capital Allocation
CUE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cue Biopharma, Inc. (CIK: 0001645460)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CUE
What is the AI rating for CUE?
Cue Biopharma, Inc. (CUE) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CUE's key strengths?
Claude: Strong liquidity position with $27.1M cash and 2.74x current ratio providing near-term operational flexibility. Dramatic 7,793% revenue growth suggests early commercialization or partnerships beginning to generate income. ChatGPT: Strong liquidity with $27.14M in cash and a 2.74x current ratio. No long-term debt, which reduces balance-sheet risk.
What are the risks of investing in CUE?
Claude: Severe cash burn of -$21.9M free cash flow with only 14 months of runway at current burn rate before insolvency. Operating margin of -96.7% and net margin of -96.9% indicate fundamental unprofitability and no path to profitability visible. ChatGPT: Operating and net margins remain near -97%, showing severe unprofitability. Free cash flow of -$21.86M indicates continued heavy cash burn.
What is CUE's revenue and growth?
Cue Biopharma, Inc. reported revenue of $27.5M.
Does CUE pay dividends?
Cue Biopharma, Inc. does not currently pay dividends.
Where can I find CUE SEC filings?
Official SEC filings for Cue Biopharma, Inc. (CIK: 0001645460) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CUE's EPS?
Cue Biopharma, Inc. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CUE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cue Biopharma, Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CUE stock overvalued or undervalued?
Valuation metrics for CUE: ROE of -100.6% (sector avg: 15%), net margin of -96.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CUE stock in 2026?
Our dual AI analysis gives Cue Biopharma, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CUE's free cash flow?
Cue Biopharma, Inc.'s operating cash flow is $-21.7M, with capital expenditures of $177.0K. FCF margin is -79.6%.
How does CUE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -96.9% (avg: 12%), ROE -100.6% (avg: 15%), current ratio 2.74 (avg: 2).